Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma Journal Article


Authors: Mondello, P.; Derenzini, E.; Asgari, Z.; Philip, J.; Brea, E. J.; Seshan, V.; Hendrickson, R. C.; de Stanchina, E.; Scheinberg, D. A.; Younes, A.
Article Title: Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
Abstract: Phosphoinositide 3-kinase (PI3K) and Myc are known to cooperate in promoting the survival and growth of a variety of B-cell lymphomas. While currently there are no small molecule inhibitors of Myc protein, histone deacetylase (HDAC) inhibitors have been shown to reduce levels of Myc protein by suppressing its transcription. We assessed the efficacy of CUDC-907, a new rationally designed dual inhibitor of PI3K and HDACs, in a panel of lymphoma cell lines. CUDC-907 treatment resulted in a dose- and time-dependent growth inhibition and cell death of DLBCL cell lines, irrespective of the cell of origin. CUDC-907 treatment down-regulated the phosphorylation of PI3K downstream targets, including AKT, PRAS40, S6, and 4EBP1, increased histone 3 acetylation, and decreased Myc protein levels. SILAC-based quantitative mass spectrometry demonstrated that CUDC-907 treatment decreased the protein levels of several components of the B cell receptor (BCR) and Toll like receptor (TLR) pathways, including BTK, SYK, and MyD88 proteins. These cellular changes were associated with an inhibition of NF-kB activation. CUDC-907 demonstrated in vivo efficacy with no significant toxicity in a human DLBCL xenograft mouse model. Collectively, these data provide a mechanistic rationale for evaluating CUDC-907 for the treatment of patients with Myc and PI3K-dependent lymphomas.
Keywords: pi3k; myc; dlbcl; bcr pathway
Journal Title: Oncotarget
Volume: 8
Issue: 8
ISSN: 1949-2553
Publisher: Impact Journals  
Date Published: 2017-02-21
Start Page: 14017
End Page: 14028
Language: English
DOI: 10.18632/oncotarget.14876
PROVIDER: scopus
PUBMED: 28147336
PMCID: PMC5355158
DOI/URL:
Notes: Article -- Export Date: 3 April 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Venkatraman Ennapadam Seshan
    382 Seshan
  2. Zahra Asgari
    11 Asgari
  3. John Philip
    48 Philip
  4. Anas Younes
    319 Younes
  5. Elliott Joseph Brea
    17 Brea